The therapy was well tolerated in the trial and showed the ability to cross the blood-brain barrier. The levels of the therapy in the CSF were comparable to or exceeded those in plasma ...
“A-005 is the first reported allosteric TYK2 inhibitor that has demonstrated the ability to cross the human blood-brain barrier to ... the cerebral spinal fluid (CSF). A-005 levels in the ...